(Total Views: 762)
Posted On: 07/01/2020 11:22:34 PM
Post# of 145248
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
I suspect that the FDA has advised NP of the minimum number of patients for a potentially approvable interim submission of severe trial data. So it is necessary for NP to delay the submission by a week or two or three. In the meantime, NP will already have potentially rocked the world with approvable data from the m to m trial, a lane that Cytodyn would have to itself. And since coronavirus is not diminishing in its impact on our country any time soon, I am not concerned (from a strictly business point of view) by a few weeks delay in the severe trial data release.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)